CTOs on the Move

Cansortium

www.cansortium.com

 
Cansortium Holdings utilizes a unique combination of capital and expertise in making strategic investments to help launch mature and professional cannabis markets. As global regulations evolve, Consortium Holdings is well-positioned to expand its presence in the U.S. and Puerto Rico.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Cansortium raised $17.1M on 04/05/2021
Cansortium raised $71M on 04/30/2021

Similar Companies

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Strategyx

Strategyx is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lawrence General Hospital

Drawing inspiration from the pioneering women and community leaders who helped establish the Hospital in 1875, Lawrence General has remained focused throughout its history to serve the community as a private, not-for-profit acute care hospital. The Hospital’s physicians and caregivers offer treatment to all patients, regardless of race, color, creed, or national origin. Every member of the clinical team works to assure the quality and level of care the Hospital provides, supporting community education and research to improve the health of the Merrimack Valley and its citizens.

Hi-Tech Pharmacal Co Inc

Hi-Tech Pharmacal Co Inc is a Amityville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)